Biomed Industries to Advance NA-931 Into Two Global Phase 3 Trials as Monotherapy and in Combination With Semaglutide and Tirzepatide for Obesity Advancing NA-931 into two Phase 3 programs as ...
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused ...
ZHENJIANG, China--(BUSINESS WIRE)--At 10:16 on January 17, State Grid Zhenjiang Power Supply Company successfully resolved a phase loss fault between Poles 17 and 18 on the 10 kV Antou 292 line of the ...
A new phase shifter does not need clean-room facilities for fabrication, so is inexpensive to manufacture. The liquid-metal enabled phase shifting elements have a 'passive' nature, unlike the 'active' ...
Based on successful Phase 3 trial results, that approval is expected to come over the next few months. This new data, announced in a press release from pharma company Eli Lilly and yet to be ...
Eli Lilly (NYSE:LLY) reported full results from a phase 3 trial of its drug Mounjaro (tirzepatide) to treat obesity or overweight in Nature Medicine and also presented it at the ObesityWeek 2023 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback